Pre-operative Tirzepatide reduces spinal fusion complications and revisions compared to GLP-1RAs in obese patients.
Background
The rising prevalence of obesity and Type 2 diabetes mellitus (T2DM) significantly complicates surgical outcomes, particularly for spinal fusion surgery. These conditions are associated with increased risks of perioperative complications, including infections, thrombotic events, and poor wound healing, which can lead to higher revision rates and prolonged recovery. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promise in improving surgical outcomes by addressing metabolic dysfunction. However, the differential impact of dual GLP-1/GIP agonists like Tirzepatide versus single receptor GLP-1 agonists (srGLP-1) on specific spinal fusion outcomes in obese patients remains an important area of investigation.
Study Design
This retrospective, propensity score-matched cohort study analyzed data from the TriNetX Research Network. Researchers identified 918 matched pairs of obese patients undergoing spinal fusion. One group received Tirzepatide alone in the 6 months preceding surgery, while the comparator group received an srGLP-1 agonist alone in the year prior to surgery. Patients were 1:1 matched based on demographics, comorbidities, medication use, and surgical procedure. Early 90-day outcomes assessed included UTI, thrombotic/embolic events, and AKI. Long-term 2-year outcomes included revision surgery, pseudarthrosis, and post-laminectomy syndrome.
Results
In the analysis of 918 matched pairs, Tirzepatide users demonstrated significantly improved outcomes across multiple endpoints compared to srGLP-1 users. At 90-days post-surgery, Tirzepatide patients experienced fewer embolic or thrombotic events (RR 0.41, 95% CI 0.22-0.76, p=0.003), lower UTI rates (RR 0.47, 95% CI 0.32-0.69, p<0.001), and fewer AKIs (RR 0.42, 95% CI 0.26-0.69, p<0.001). These early benefits extended to long-term outcomes at 2 years.
Tirzepatide users had significantly fewer instances of
pseudarthrosis(RR 0.41, 95% CI 0.25-0.68, p<0.001), revision surgery (RR 0.65, 95% CI 0.49-0.87, p=0.003), andpost-laminectomy syndrome(RR 0.58, 95% CI 0.31-0.68, p<0.001). These findings highlight a substantial protective physiological impact of Tirzepatide oversrGLP-1sin this high-risk surgical population.
Key Findings
- Pre-operative Tirzepatide cut 90-day embolic/thrombotic events by 59% (RR 0.41, p=0.003) vs.
srGLP-1in obese spinal fusion patients. - Tirzepatide reduced 90-day
UTIrates by 53% (RR 0.47, p<0.001) andAKIrates by 58% (RR 0.42, p<0.001) vs.srGLP-1. - At 2 years, Tirzepatide users had 35% fewer revision surgeries (RR 0.65, p=0.003) compared to
srGLP-1users. - Tirzepatide significantly lowered
pseudarthrosisrates by 59% (RR 0.41, p<0.001) at 2 years post-surgery. - Tirzepatide reduced
post-laminectomy syndromeby 42% (RR 0.58, p<0.001) at 2 years.
Why It Matters
This study provides compelling real-world evidence that Tirzepatide may offer superior pre-operative optimization for obese patients undergoing spinal fusion compared to single-receptor GLP-1 agonists. Clinicians should consider Tirzepatide as a potentially preferred agent for metabolic optimization in obese patients awaiting spinal fusion to reduce both early and long-term complications. For individuals managing obesity or T2DM and contemplating spinal surgery, this suggests a specific class of medication could significantly improve surgical success and recovery. While this is a retrospective study, the robust matching and significant effect sizes indicate a strong signal for Tirzepatide's protective effects, potentially influencing pre-surgical protocols and shared decision-making regarding medication choices.
tirzepatide
glp-1-agonist
gip-agonist
obesity
spinal-fusion
surgery